Home Cart Sign in  
Chemical Structure| 1034616-18-6 Chemical Structure| 1034616-18-6

Structure of Onvansertib
CAS No.: 1034616-18-6

Chemical Structure| 1034616-18-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor (IC50=2 nM) with potential antineoplastic activity and no inhibition on PLK2 and PLK3.

Synonyms: NMS-P937; Nms-1286937; PCM-075

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Onvansertib

CAS No. :1034616-18-6
Formula : C24H27F3N8O3
M.W : 532.52
SMILES Code : O=C(C1=NN(CCO)C2=C1CCC3=CN=C(NC4=CC(N5CCN(C)CC5)=CC=C4OC(F)(F)F)N=C23)N
Synonyms :
NMS-P937; Nms-1286937; PCM-075
MDL No. :MFCD26793840
InChI Key :QHLVBNKYJGBCQJ-UHFFFAOYSA-N
Pubchem ID :49792852

Safety of Onvansertib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PLK1

    PLK1, IC50:2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
C4-2 CRPC cells 15 nM 16 hours To evaluate the synergistic effect of Onvansertib with Abiraterone, results showed that the combination of Abiraterone and Onvansertib significantly increased mitotic arrest and apoptosis. PMC9852064
LNCaP cells 30 nM 16 hours To evaluate the synergistic effect of Onvansertib with Abiraterone, results showed that LNCaP cells did not exhibit a synergistic effect. PMC9852064
DU145 cells 10 nM 12 hours To evaluate the synergistic effect of Onvansertib with Abiraterone, results showed that DU145 cells exhibited synergistic G2/M arrest and apoptosis. PMC9852064
D283 4.90 nM Onvansertib significantly inhibited the survival of D283 cells. PMC8917408
D425 5.67 nM Onvansertib significantly inhibited the survival of D425 cells. PMC8917408
D458 6.00 nM Onvansertib significantly inhibited the survival of D458 cells. PMC8917408
HDMB03 5.67 nM Onvansertib significantly inhibited the survival of HDMB03 cells. PMC8917408
ONS-76 14.36 nM Onvansertib significantly inhibited the survival of ONS-76 cells. PMC8917408
UW228 27.94 nM Onvansertib significantly inhibited the survival of UW228 cells. PMC8917408
NHA 131.60 nM Onvansertib showed weaker inhibitory effect on NHA cells. PMC8917408
CAL33 10 nM and 25 nM 24 h Onvansertib inhibited the formation of clones in both sensitive and resistant CAL33 cells, induced G2/M phase arrest, increased chromosomal abnormalities and polyploidy, ultimately leading to apoptosis. PMC8490521
CAL27 10 nM and 25 nM 24 h Onvansertib inhibited the formation of clones in both sensitive and resistant CAL27 cells, induced G2/M phase arrest, increased chromosomal abnormalities and polyploidy, ultimately leading to apoptosis. PMC8490521
Ovcar-3 cells 30 or 50 nM 6 days The combination of onvansertib and olaparib showed additive or synergistic effects in Ovcar-3 cells, leading to increased G2/M cell cycle arrest, DNA damage, and apoptosis. PMC11263393
ES-2 cells 30 or 50 nM 6 days The combination of onvansertib and olaparib showed additive or synergistic effects in ES-2 cells, leading to increased G2/M cell cycle arrest, DNA damage, and apoptosis. PMC11263393
EFO27 150 nM 72 hours To validate the synthetic lethality effect of Onvansertib with JUND, CARD9, and BCL2L2 genes, showing significant reduction in cell viability. PMC11765470
OCM.72 13.19 ± 1.43 µM 5 days To test the cytotoxicity of SENP1 inhibitor Momordin Ic in OCM.72 cells, showing an IC50 of 10.68 µM. PMC11765470
MCF7 25 nM 24 h To evaluate the effect of Onvansertib in combination with Alpelisib on apoptosis in MCF7 cells. The results showed that the combination significantly increased the proportion of apoptotic cells. PMC11476299
EFM-19 15 nM 24 h To evaluate the effect of Onvansertib in combination with Alpelisib on apoptosis in EFM-19 cells. The results showed that the combination significantly increased the proportion of apoptotic cells. PMC11476299

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice LVCaP-2CR PDX model oral 50 mg/kg 5 days per week for 2 weeks To evaluate the synergistic effect of Onvansertib with Abiraterone in vivo, results showed that the combination significantly inhibited tumor growth and increased mitotic arrest. PMC9852064
Mice D458 cell xenograft model Oral 4% glutamine 5 consecutive days, lasting for 8 weeks Onvansertib significantly inhibited tumor growth in the D458 xenograft model and extended the survival of mice. PMC8917408
Nude mice CAL33 and CAL33RR tumor models Oral 60 mg/kg Onvansertib, 196 mg/kg Abiraterone 5 consecutive days of treatment, followed by a 24 to 48-hour drug holiday Onvansertib significantly inhibited the growth of CAL33 and CAL33RR tumors, reduced tumor volume, and induced tumor necrosis. Additionally, Onvansertib reduced the number of proliferating cells and blood vessel density in the tumors. PMC8490521
Mice BRCA1-mutated ovarian cancer models Oral 100 mg/kg Three times a week, continuous treatment The combination of onvansertib and olaparib showed significant tumor growth inhibition and prolonged survival in BRCA1-mutated ovarian cancer models, with good tolerability. PMC11263393
Female Swiss nude mice PIK3CA-mutant HR+ breast cancer PDX models Oral 1.5 mg/kg/day Once daily for 2 weeks To evaluate the anti-tumor activity of Onvansertib in combination with Alpelisib in PIK3CA-mutant HR+ breast cancer PDX models. The results showed that the combination demonstrated significant anti-tumor activity, which was superior to the single agents in all three PDX models. PMC11476299

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05450965 Small-cell Lung Cancer|Small C... More >>ell Lung Carcinoma Less << PHASE2 RECRUITING 2027-11-30 University of Maryland Greeneb... More >>aum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.39mL

1.88mL

0.94mL

18.78mL

3.76mL

1.88mL

References

 

Historical Records

Categories